Prid delta Leggangainnlegg 1,55 g Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

prid delta leggangainnlegg 1,55 g

ceva santé animale* - progesteronum inn - leggangainnlegg - 1,55 g

Cyclogest Leggangastíll 400 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cyclogest leggangastíll 400 mg

gedeon richter plc.* - progesteronum inn - leggangastíll - 400 mg

Ioa Evrópusambandið - íslenska - EMA (European Medicines Agency)

ioa

n.v. organon - nomegestrol myndir, eitilfrumur - getnaðarvörn - hormón kynlíf og stillum kynfæri - getnaðarvörn til inntöku.

Yselty Evrópusambandið - íslenska - EMA (European Medicines Agency)

yselty

theramex ireland limited - linzagolix choline - leiomyoma - hinsveiflur og heilahimnubólur og hliðstæður - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Bridion Evrópusambandið - íslenska - EMA (European Medicines Agency)

bridion

merck sharp & dohme b.v. - sugammadex - taugakerfi - Öll önnur lækningavörur - afturköllun taugavöðvablokkunar sem valdið er af rócuronium eða vecuronium. fyrir peadiatric íbúafjöldi: sugammadex er einungis fyrir lífi viðsnúningur rocuronium völdum umsátur í börn og unglingar.

Sugammadex Mylan Evrópusambandið - íslenska - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Fresenius Kabi Evrópusambandið - íslenska - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.